FDA Approves Asciminib for Patients With Chronic Myeloid Leukemia

The FDA has granted accelerated approval to asciminib (Scemblix®, Novartis AG) for patients with Philadelphia chromosome–positive (Ph-positive) chronic myeloid leukemia (CML) who have disease in chronic phase and were previously treated with two or more tyrosine kinase inhibitors and for those whose disease is in chronic phase with the T315I mutation."Patients with CML in chronic phase CML resistant or intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outco...
Continue reading

Management of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors With Sara Tinsley, PhD, ARNP, AOCN

Chronic myeloid leukemia (CML) accounts for 15% of all adult leukemias and is characterized by heterogenous clinical manifestations. In recent years outcomes for patients with CML have greatly improved, in part due to the advent of tyrosine kinase inhibitor (TKI) therapy. At the Oncology Nursing Society 43rd Annual Congress in Washington, DC, i3 Health spoke with Sara Tinsley, PhD, ARNP, AOCN, from Moffitt Cancer Center, about therapeutic advances in CML and the importance of ensuring patient ad...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.